At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Radiation therapy (radiation)
- How long the study runs
- Study runs about 138 months (dates as stated)
- About the drug or intervention
- Radiation therapy — radiation: Radiation therapy on the CE marked and FDA approved MR-Linac
- Patient visit burden
- Not specified by the sponsor
In plain English
The MOMENTUM Study looks at outcomes for people who have imaging or treatment on an MR-Linac, a machine that combines a magnetic resonance imaging (MRI) scanner with a radiotherapy machine. It covers many types of cancer, including breast, prostate, lung, bowel, pancreatic, liver, head and neck, brain and bladder cancer. The study also looks at radiation side effects and quality of life.
Who can take part
- You are having or have had imaging or treatment on an MR-Linac machine
- You give written informed consent
- You are 18 years old or older
Who may not be able to
- You cannot have an MRI for the usual clinical reasons, such as being (possibly) pregnant, claustrophobia, or having metal or electronic implants that are not safe with MRI
What taking part involves
- • Imaging or treatment procedures on an MR-Linac — a machine that combines an MRI scanner with a radiotherapy machine
- • Information is collected about treatment outcomes, radiation side effects and quality of life — further details not stated; ask the trial team
Time commitment: Not stated — ask the trial team about visits, duration and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 8,000
- Started
- 2019-02-01
- Last checked
- 2026-01
Plain English Summary
What is this study?
- • Testing a new treatment for oncology
- • Clinical study - 8,000 participants
- • The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with oncology
Where?
- • London - The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre
- • Manchester - The Christie National Health Service Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
More detail
Rationale: Radiation therapy has become indispensable in cancer treatment. However, it is associated with severe side effects. Innovation in radiation therapy has resulted in the development of MR-guided radiation therapy (MRGRT) which allows high precision radiotherapy under real time MR visualization. High precision MRGRT has the potential of dose escalation and margin reduction and may potentially lead to higher cure rates and less toxicity. MRGRT can be delivered by the MRI guided Linear Accelerator (MR-Linac) which integrates a state-of-the-art linear accelerator, 1.5T diagnostic quality MRI and an online adaptive workflow. Objective: The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study (MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and Biologic MRGRT and facilitate the evidence-based introduction of the MR-Linac into clinical practice. In MOMENTUM, technical and clinical data are gathered in order to optimize software, evaluate treatment outcomes, toxicities and progression free, disease free, and overall survival per disease site, and create a repository of anatomical and biological MR sequences to develop new features. Study design: A multi-institutional, international observational cohort study. Study population: Cancer patients ≥ 18 years receiving treatment and/or imaging on an MR-Linac machine are eligible for enrollment. Main study parameters/endpoints: MOMENTUM will collect technical and clinical patient data. The technical patient data is defined as data generated by (the use of) the MR-Linac and will include data collection during scans performed during routine care as well as research MRIs. Clinical data will be categorized into six classes: demographic, disease characteristics, treatment classifiers, toxicity outcomes, cancer control outcomes and PROs.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;
- ✓Patient provides written, agreement to take part;
- ✓Patient is 18 years old or older.
Who cannot take part
- ✗MRI exclusion criteria, including
- ✗MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or...
See the full criteria
Where Is This Study? (2 UK sites)
The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre
London, United Kingdom
The Christie National Health Service Foundation Trust
Manchester, United Kingdom
How to Get in Touch
Tessa Leer
Sponsor contactCONTACT